Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darusentan for resistant hypertension
ACTRN12606000292572Phase 3Recruiting
- Sponsor
- Myogen
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darusentan in resistant hypertension (RH), sponsored by Myogen. Primary endpoint: Change from baseline in trough sitting systolic blood pressure measured by sphygmomanometry. Started Sep 2006; status: recruiting.
02
Drugs
darusentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on ACTRN12606000292572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000292572.